Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 19,140,000 shares, a growth of 11.0% from the October 31st total of 17,250,000 shares. Based on an average trading volume of 3,040,000 shares, the days-to-cover ratio is currently 6.3 days. Approximately 18.5% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on HUMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Humacyte in a research report on Wednesday, November 13th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $13.00.

Insider Buying and Selling at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laura E. Niklason sold 157,704 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the transaction, the chief executive officer now directly owns 3,519,558 shares of the company’s stock, valued at $19,076,004.36. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,662,886 shares of company stock valued at $7,489,538. 11.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. nVerses Capital LLC purchased a new position in Humacyte during the second quarter worth approximately $28,000. Concurrent Investment Advisors LLC purchased a new position in shares of Humacyte during the 3rd quarter worth $75,000. Principal Financial Group Inc. purchased a new position in shares of Humacyte during the 2nd quarter worth $83,000. FORA Capital LLC acquired a new position in shares of Humacyte during the 3rd quarter valued at about $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte in the second quarter valued at about $97,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Stock Performance

HUMA opened at $4.25 on Wednesday. Humacyte has a twelve month low of $2.45 and a twelve month high of $9.97. The firm has a market capitalization of $534.91 million, a PE ratio of -3.17 and a beta of 1.38. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. The firm’s 50-day moving average price is $5.17 and its 200 day moving average price is $6.13.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.